These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26597964)

  • 1. Pathogenesis and Therapeutic Strategies in Alzheimer's Disease: From Brain to Periphery.
    Yu JT; Zhang C
    Neurotox Res; 2016 Feb; 29(2):197-200. PubMed ID: 26597964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.
    Xiang Y; Bu XL; Liu YH; Zhu C; Shen LL; Jiao SS; Zhu XY; Giunta B; Tan J; Song WH; Zhou HD; Zhou XF; Wang YJ
    Acta Neuropathol; 2015 Oct; 130(4):487-99. PubMed ID: 26363791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives.
    Cheng Y; Tian DY; Wang YJ
    Transl Neurodegener; 2020 May; 9(1):16. PubMed ID: 32381118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
    Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
    Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
    Zhang Y; Lee DH
    Neuroscientist; 2011 Apr; 17(2):163-73. PubMed ID: 21330304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products.
    Awasthi M; Singh S; Pandey VP; Dwivedi UN
    J Neurol Sci; 2016 Feb; 361():256-71. PubMed ID: 26810552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle?
    Watt AD; Villemagne VL; Barnham KJ
    J Alzheimers Dis; 2013; 33 Suppl 1():S283-93. PubMed ID: 22699851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.
    Liu YH; Wang YR; Xiang Y; Zhou HD; Giunta B; Mañucat-Tan NB; Tan J; Zhou XF; Wang YJ
    Mol Neurobiol; 2015 Feb; 51(1):1-7. PubMed ID: 24733588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery.
    Ullah R; Park TJ; Huang X; Kim MO
    Ageing Res Rev; 2021 Nov; 71():101451. PubMed ID: 34450351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.
    Asih PR; Chatterjee P; Verdile G; Gupta VB; Trengove RD; Martins RN
    Neurodegener Dis Manag; 2014; 4(5):363-78. PubMed ID: 25405650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Androgens on the Amyloid-β Protein in Alzheimer's Disease.
    Lei Y; Renyuan Z
    Endocrinology; 2018 Dec; 159(12):3885-3894. PubMed ID: 30215697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets.
    Han SH; Park JC; Mook-Jung I
    Prog Neurobiol; 2016 Feb; 137():17-38. PubMed ID: 26721621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could ecosystem management provide a new framework for Alzheimer's disease?
    Hubin E; Vanschoenwinkel B; Broersen K; De Deyn PP; Koedam N; van Nuland NA; Pauwels K
    Alzheimers Dement; 2016 Jan; 12(1):65-74.e1. PubMed ID: 26341147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease.
    Tian L; Zhang K; Tian ZY; Wang T; Shang DS; Li B; Liu DX; Fang WG; Wang ZY; Chen YH
    J Alzheimers Dis; 2014; 42(2):511-20. PubMed ID: 24898658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the cause of sporadic Alzheimer's disease.
    Zetterberg H; Mattsson N
    Expert Rev Neurother; 2014 Jun; 14(6):621-30. PubMed ID: 24852227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
    Ling S; Zhou J; Rudd JA; Hu Z; Fang M
    Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis.
    Lucey BP; Bateman RJ
    Neurobiol Aging; 2014 Sep; 35 Suppl 2():S29-34. PubMed ID: 24910393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.
    Galozzi S; Marcus K; Barkovits K
    Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.